Personne
Hilal Lashuel
Publications associées (190)
Post-translational glycosylation diminishes α-synuclein pathology formation
O-linked N-acetylglucosamine (O-GlcNAc) is an endogenous form of glycosylation that alters the structure of alpha-synuclein amyloid fibrils and attenuates their pathogenetic properties. The modified fibrils have a significantly reduced ability to seed the ...
Berlin2024Method of preparation of amyloidogenic protein aggregates and uses thereof
Hilal Lashuel, Galina Limorenko
The invention relates to methods for the preparation of method of preparation of Tau aggregates, including fibrils, fibrillar species, soluble and insoluble oligomeric species, new Tau aggregates and uses thereof. The invention further relates to the uses ...
2024Overexpression of human alpha-Synuclein leads to dysregulated microbiome/metabolites with ageing in a rat model of Parkinson disease
Hilal Lashuel, Florian Lang, Joan Romani Aumedes, Yogesh Singh
Background Braak's hypothesis states that sporadic Parkinson's disease (PD) follows a specific progression of pathology from the peripheral to the central nervous system, and this progression can be monitored by detecting the accumulation of alpha-Synuclei ...
BMC2023Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases
Hilal Lashuel, Johannes Burtscher, Melek Firat Altay, Somanath Jagannath
The abnormal aggregation and accumulation of alpha-synuclein (aSyn) in the brain is a defining hallmark of synucleinopathies. Various aSyn conformations and post-translationally modified forms accumulate in pathological inclusions and vary in abundance amo ...
Berlin2023Effective Inhibition of TDP-43 Aggregation by Native State Stabilization
Hilal Lashuel, Yllza Jasiqi, Lixin Yang
Preventing the misfolding or aggregation of transactive response DNA binding protein with 43 kDa (TDP-43) is the most actively pursued disease-modifying strategy to treat amyotrophic lateral sclerosis and other neurodegenerative diseases. In this work, we ...
Weinheim2023Recombinant Full-Length TDP-43 Oligomers Retain Their Ability to Bind RNAs, Are Not Toxic, and Do Not Seed TDP-43 Aggregation in Vitro
Hilal Lashuel, Yllza Jasiqi, Lixin Yang
TAR DNA-binding protein with 43 kD (TDP-43) is a partially disordered protein that misfolds and accumulates in the brains of patients affected by several neurodegenerative diseases. TDP-43 oligomers have been reported to form due to aberrant misfolding or ...
Washington2023Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies
Hilal Lashuel, Pedro José Santana Ribeiro Magalhães
Parkinson's disease (PD), the second most common progressive neurodegenerative disease, develops and progresses for 10-15 years before the clinical diagnostic symptoms of the disease are manifested. Furthermore, several aspects of PD pathology overlap with ...
NATURE PORTFOLIO2022Comparative Analysis of Total Alpha-Synuclein (alpha SYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified alpha SYN Proteoforms
Hilal Lashuel, Lorène Aeschbach, Lara Petricca, Mohamed Bilal Fares, Ritwik Burai, Layane Hanna-el-Daher
Background: The development of therapeutics for Parkinson's disease (PD) requires the establishment of biomarker assays to enable stratifying patients, monitoring disease progression, and assessing target engagement. Attempts to develop diagnostic assays b ...
IOS PRESS2022Pathological substrate of memory impairment in multiple system atrophy
Hilal Lashuel, Melek Firat Altay
Aims: Synaptic dysfunction in Parkinson's disease is caused by propagation of pathogenic alpha-synuclein between neurons. Previously, in multiple system atrophy (MSA), pathologically characterised by ectopic deposition of abnormal alpha-synuclein predomina ...
WILEY2022Alpha-synuclein as a Potential Biomarker for Parkinson’s Disease and Other Synucleinopathies: Gaps, Challenges, and Opportunities
Parkinson's disease (PD), the second most common progressive neurodegenerative disease, develops and progresses for 10-15 years before the clinical diagnostic symptoms of the disease are manifested. Furthermore, several aspects of PD pathology overlap with ...
2022